Unknown

Dataset Information

0

Chimeric oligosaccharide conjugate induces opsonic antibodies against Streptococcus pneumoniae serotypes 19A and 19F.


ABSTRACT: Streptococcus pneumoniae 19A (ST19A) and 19F (ST19F) are among the prevalent serotypes causing pneumococcal disease worldwide even after introduction of a 13-valent pneumococcal conjugate vaccine (PCV13). Synthetic glycoconjugate vaccines have defined chemical structures rather than isolated polysaccharide mixtures utilized in marketed vaccines. Ideally, a minimal number of synthetic antigens would cover as many bacterial serotypes to lower cost of goods and minimize the response to carrier proteins. To demonstrate that a chimeric oligosaccharide antigen can induce a protective immune response against multiple serotypes, we synthesized a chimeric antigen (ST19AF) that is comprised of a repeating unit of ST19A and ST19F capsular polysaccharide each. Synthetic glycan epitopes representing only ST19A, and ST19F were prepared for comparison. Semisynthetic glycoconjugates containing chimeric antigen ST19AF induced high antibody titers able to recognize native CPS from ST19A and ST19F in rabbits. The antibodies were able to kill both strains of pneumococci. Chimeric antigens are an attractive means to induce an immune response against multiple bacterial serotypes.

SUBMITTER: Sanapala SR 

PROVIDER: S-EPMC8159444 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Chimeric oligosaccharide conjugate induces opsonic antibodies against <i>Streptococcus pneumoniae</i> serotypes 19A and 19F.

Sanapala Someswara Rao SR   Seco Bruna M S BMS   Baek Ju Yuel JY   Awan Shahid I SI   Pereira Claney L CL   Seeberger Peter H PH  

Chemical science 20200626 28


<i>Streptococcus pneumoniae</i> 19A (ST19A) and 19F (ST19F) are among the prevalent serotypes causing pneumococcal disease worldwide even after introduction of a 13-valent pneumococcal conjugate vaccine (PCV13). Synthetic glycoconjugate vaccines have defined chemical structures rather than isolated polysaccharide mixtures utilized in marketed vaccines. Ideally, a minimal number of synthetic antigens would cover as many bacterial serotypes to lower cost of goods and minimize the response to carri  ...[more]

Similar Datasets

| S-EPMC10084702 | biostudies-literature
| S-EPMC8453487 | biostudies-literature
| S-EPMC3221484 | biostudies-other
| S-EPMC5234679 | biostudies-literature
| S-EPMC1169178 | biostudies-literature
| S-EPMC9009640 | biostudies-literature
| S-EPMC2851619 | biostudies-literature
| S-EPMC5911667 | biostudies-literature
| S-EPMC6375853 | biostudies-literature
| S-EPMC6509521 | biostudies-literature